drugset / Trial / NCT00569192
A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children
Phase 3
Completed
360 enrolled
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to examine the safety and efficacy of two doses of MAP0010 versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week treatment period.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-09
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 0.135 mg | Other |
| Subject | Budesonide | Small molecule | 0.25 mg | Other |